LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

4.11 6.75

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.83

Max

4.11

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+293.08% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-24M 231M
Iepriekšējā atvēršanas cena	-2.64
Iepriekšējā slēgšanas cena	4.11

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. marts 18:13 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

2026. g. 9. marts 17:20 UTC

Galvenie ziņu notikumi

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

2026. g. 9. marts 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

2026. g. 10. marts 00:00 UTC

Galvenie ziņu notikumi

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

2026. g. 9. marts 23:52 UTC

Tirgus saruna

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

2026. g. 9. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

2026. g. 9. marts 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Crude Prices Market Talk on March 9

2026. g. 9. marts 23:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

2026. g. 9. marts 23:08 UTC

Galvenie ziņu notikumi

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

2026. g. 9. marts 23:07 UTC

Galvenie ziņu notikumi

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

2026. g. 9. marts 21:29 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue Now Fully Owns Peru's Canariaco Copper Project

2026. g. 9. marts 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue Completes Acquisition of Remaining Alta Copper Shares

2026. g. 9. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. marts 20:47 UTC

Galvenie ziņu notikumi

The 24 Hours When Oil Markets Went Wild -- WSJ

2026. g. 9. marts 20:33 UTC

Galvenie ziņu notikumi

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

2026. g. 9. marts 20:14 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

2026. g. 9. marts 19:33 UTC

Galvenie ziņu notikumi

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

2026. g. 9. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

2026. g. 9. marts 19:14 UTC

Tirgus saruna

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

2026. g. 9. marts 19:00 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026. g. 9. marts 18:23 UTC

Tirgus saruna

Galvenie ziņu notikumi

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

2026. g. 9. marts 17:58 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

2026. g. 9. marts 17:57 UTC

Iegādes, apvienošanās, pārņemšana

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

2026. g. 9. marts 17:41 UTC

Galvenie ziņu notikumi

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

2026. g. 9. marts 17:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

2026. g. 9. marts 17:08 UTC

Tirgus saruna

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

2026. g. 9. marts 17:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. marts 17:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

293.08% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD 293.08%

Augstākais 25 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.